De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Kontafarma China Holdings Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Kontafarma China Holdings is gedaald met een gemiddeld jaarlijks percentage van -34.9%, terwijl de winst van de Pharmaceuticals -industrie jaarlijks groeide met 5.7%. De inkomsten zijn daalde met een gemiddeld percentage van 7.3% per jaar.

Belangrijke informatie

-34.9%

Groei van de winst

-34.9%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie	5.6%
Inkomstengroei	-7.3%
Rendement op eigen vermogen	-8.2%
Nettomarge	-7.6%
Laatste winstupdate	30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

Is Kontafarma China Holdings (HKG:1312) Weighed On By Its Debt Load?

Sep 04

Here's Why Kontafarma China Holdings Limited's (HKG:1312) CEO Compensation Is The Least Of Shareholders Concerns

May 31

There's No Escaping Kontafarma China Holdings Limited's (HKG:1312) Muted Revenues Despite A 61% Share Price Rise

May 24

Health Check: How Prudently Does Tongfang Kontafarma Holdings (HKG:1312) Use Debt?

Sep 15

Tongfang Kontafarma Holdings (HKG:1312) Has Debt But No Earnings; Should You Worry?

Apr 20

Is Tongfang Kontafarma Holdings (HKG:1312) A Risky Investment?

Nov 04

Tongfang Kontafarma Holdings' (HKG:1312) Shareholders Are Down 90% On Their Shares

Feb 18

These 4 Measures Indicate That Tongfang Kontafarma Holdings (HKG:1312) Is Using Debt Extensively

Dec 07

Opbrengsten en kosten

Hoe Kontafarma China Holdings geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

SEHK:1312 Opbrengsten, kosten en inkomsten (HKD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven
30 Jun 24	837	-63	512
31 Mar 24	823	-46	528
31 Dec 23	809	-29	543
30 Sep 23	841	-12	541
30 Jun 23	874	5	536
31 Mar 23	884	-40	549
31 Dec 22	894	-85	562
30 Sep 22	997	-24	575
30 Jun 22	869	-10	536
31 Mar 22	836	-29	498
31 Dec 21	803	-48	460
30 Jun 21	938	-119	509
31 Mar 21	974	-81	508
31 Dec 20	1,009	-42	508
30 Jun 20	661	66	473
31 Mar 20	791	60	467
31 Dec 19	921	54	460
30 Sep 19	1,280	29	459
30 Jun 19	1,666	22	428
31 Mar 19	1,880	27	414
31 Dec 18	2,094	32	400
30 Sep 18	1,985	12	370
30 Jun 18	1,876	-8	340
31 Mar 18	1,610	-5	306
31 Dec 17	1,344	-2	272
30 Sep 17	1,175	-15	243
30 Jun 17	1,006	-27	213
31 Mar 17	820	-32	172
31 Dec 16	633	-37	131
30 Sep 16	539	-43	95
30 Jun 16	445	-49	60
31 Mar 16	456	-41	62
31 Dec 15	466	-34	65
30 Sep 15	547	-18	65
30 Jun 15	628	-2	65
31 Mar 15	681	8	60
31 Dec 14	733	17	55
30 Sep 14	747	28	52
30 Jun 14	761	38	49
31 Mar 14	732	35	48
31 Dec 13	703	33	47

Kwaliteitswinsten: 1312 is momenteel verliesgevend.

Groeiende winstmarge: 1312 is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: 1312 is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 34.9% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van 1312 over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: 1312 is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Pharmaceuticals industrie ( 6.4% ).

Rendement op eigen vermogen

Hoge ROE: 1312 heeft een negatief Return on Equity ( -8.2% ), omdat het momenteel verliesgevend is.

Kontafarma China Holdings Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

First half 2024 earnings released: EPS: HK$0.001 (vs HK$0.007 in 1H 2023)

Kontafarma China Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024

Full year 2023 earnings released: HK$0.005 loss per share (vs HK$0.015 loss in FY 2022)

Kontafarma China Holdings Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

First half 2023 earnings released: EPS: HK$0.007 (vs HK$0.009 loss in 1H 2022)

Kontafarma China Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023

Recent updates

First half 2024 earnings released: EPS: HK$0.001 (vs HK$0.007 in 1H 2023)

Is Kontafarma China Holdings (HKG:1312) Weighed On By Its Debt Load?

Kontafarma China Holdings Limited Announces Board Changes, with Effect from 1 September 2024

Kontafarma China Holdings Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2024

Kontafarma China Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024

New major risk - Share price stability

Kontafarma China Holdings Limited Announces CEO Changes

Here's Why Kontafarma China Holdings Limited's (HKG:1312) CEO Compensation Is The Least Of Shareholders Concerns

There's No Escaping Kontafarma China Holdings Limited's (HKG:1312) Muted Revenues Despite A 61% Share Price Rise

New minor risk - Share price stability

Kontafarma China Holdings Limited Announces Management Changes, Effect from 19 April 2024

Full year 2023 earnings released: HK$0.005 loss per share (vs HK$0.015 loss in FY 2022)

Kontafarma China Holdings Limited, Annual General Meeting, Jun 07, 2024

Kontafarma China Holdings Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Health Check: How Prudently Does Kontafarma China Holdings (HKG:1312) Use Debt?

First half 2023 earnings released: EPS: HK$0.007 (vs HK$0.009 loss in 1H 2022)

Is Kontafarma China Holdings (HKG:1312) Using Debt Sensibly?

Kontafarma China Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023

New major risk - Share price stability

Kontafarma China Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023

Full year 2022 earnings released: HK$0.015 loss per share (vs HK$0.003 loss in FY 2021)

Is Kontafarma China Holdings (HKG:1312) Using Debt Sensibly?

Less than half of directors are independent

Health Check: How Prudently Does Tongfang Kontafarma Holdings (HKG:1312) Use Debt?

First half 2022 earnings released: HK$0.011 loss per share (vs HK$0.014 loss in 1H 2021)

Tongfang Kontafarma Holdings Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2022

Tongfang Kontafarma Holdings Limited to Report First Half, 2022 Results on Aug 29, 2022

Less than half of directors are independent

Tongfang Kontafarma Holdings (HKG:1312) Has Debt But No Earnings; Should You Worry?

Tongfang Kontafarma Holdings Limited Announces Management Changes

Full year 2021 earnings released: HK$0.003 loss per share (vs HK$0.008 loss in FY 2020)

Is Tongfang Kontafarma Holdings (HKG:1312) A Risky Investment?

Executive Director Bingzhang Wei has left the company

Less than half of directors are independent

Tongfang Kontafarma Holdings Limited Provides Earnings Guidance for the Full Year of Fiscal 2020

Tongfang Kontafarma Holdings Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

Tongfang Kontafarma Holdings' (HKG:1312) Shareholders Are Down 90% On Their Shares

These 4 Measures Indicate That Tongfang Kontafarma Holdings (HKG:1312) Is Using Debt Extensively

Minyi Holdings Limited entered into an agreement to acquire Real Jade Limited from Tongfang Kontafarma Holdings Limited (SEHK:1312) for approximately HKD 350 million.

First half earnings released

First half earnings released

Tongfang Kontafarma Holdings Limited to Report First Half, 2020 Results on Aug 28, 2020

Opbrengsten en kosten

Inkomsten en omzetgeschiedenis

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Rendement op eigen vermogen

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden